Moderate (severity modifier)

FDA Approves Over-the-Counter Hearing Aid Software for Apple AirPods Pro

7 months ago talkbio0Tagged Approved, Computer software, Genus Malus, Hearing, Hearing Aids, Moderate (severity modifier), United States Food and Drug Administration

FDA approval, over-the-counter hearing aids, Apple AirPods Pro, hearing aid software, mild to moderate hearing loss

Almirall’s Ebglyss Gains NICE Recommendation for Atopic Dermatitis Treatment

10 months ago talkbio0Tagged Biological Response Modifier Therapy, Dermatitis, Atopic, Ebglyss, England, lebrikizumab, Moderate (severity modifier), Nance-Horan syndrome, Nitroglycerin/Sodium Citrate/Ethanol Solution, Recommendation, Severe (severity modifier)

Ebglyss, lebrikizumab, atopic dermatitis, NICE recommendation, Almirall, NHS England, biological therapy, moderate to severe atopic dermatitis

Innovent Biologics’ Picankibart Achieves Success in Phase III CLEAR-1 Study for Moderate to Severe Plaque Psoriasis

11 months ago talkbio0Tagged Biological Factors, Center for Drug Evaluation, Chronic small plaque psoriasis, Class, drug application, Innovent, Interleukin-23 Subunit p19, Moderate (severity modifier), National Medical Product Administration, Phase III CLEAR-1 Study, picankibart

Innovent Biologics, picankibart, Phase III CLEAR-1 study, moderate to severe plaque psoriasis, IL-23p19 class, new drug application, Center for Drug Evaluation, National Medical Product Administration.

FDA Grants Emergency Authorization for Invivyd’s Pemgarda Antibody Prophylactic Against COVID-19 in Immunocompromised Individuals

1 year ago talkbio0Tagged Adolescent (age group), Adults/, Approved, Condoms, Male, COVID19 (disease), Emergency Use Authorization, Half-Life Extended Monoclonal Antibody, immune compromise, Immunocompromised Host, Invivyd, Moderate (severity modifier), Pemgarda, pemivibart, Pre-Exposure Prophylaxis, Prophylactic treatment, Severe (severity modifier), United States Food and Drug Administration, VYD222

Invivyd, Pemgarda (pemivibart; formerly VYD222), Half-Life Extended Monoclonal Antibody, COVID-19 Prophylactic, Immunocompromised Patients, Emergency Use Authorization (EUA), FDA Approval, Moderate to Severe Immune Compromise, Pre-exposure Prophylaxis (Prevention) of COVID-19 in Adults/ Adolescents